

ACTEMRA (TOCILIZUMAB) INFUSION ORDERS

P: 945.212.3707 | F: 866.790.3580

☐ Home Infusion □ Alternate Site of Care

PATIENT INFORMATION:	Fax completed form, insurance information, and clinical documentation to 866.790.3580
Patient Name:	DOB: Phone:
	Continuing Therapy Next Treatment Date:
MEDICAL INFORMATION	
Systemic Juvenil	nritis
ICD-10 Code:	
PatientWeight:lbs.(requir	ed)Allergies:
THERAPY ORDER	
4mg/kg IV every 4 weeks x 1 y	
PJIA: CBC w/diff, LFTs, and Lipid I	
Additional Lab Orders:	Frequency:
🗆 ТВ Q	FT Screening yearly (optional) 🗌 Baseline HepBcAB total
Required labs to be drawn by:	□ Vital Care □ Referring Provider
Other orders:	
PROVIDER INFORMATION	
agent in dealing with medical and prescription insurance of	norizing Vital Care of South Dallas and its employees to serve as your prior authorization and specialty pharmacy designated ompanies, and to select the preferred site of care for the patient.
Provider Name:	Signature: Date:
Provider NPI: Phone	Signature: Date: e: Fax: Contact Person:
Opt out of Vital Care selecting site	te of care (if checked, please list site of care):
SERVICE AREAS	
City: Stat	e:

VITALCARE.COM/LOCATIONS/VITAL-CARE-OF-SOUTH-DALLAS/

IMPORTANT NOTICE: This fax is intended to be delivered only to the named address and contains material that is confidential, privileged property, or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.



COMPREHENSIVE SUPPORT FOR ACTEMRA (TOCILIZUMAB) THERAPY

PATIENT INFORMATION:

Patient Name:

DOB: ____

REQUIRED DOCUMENTATION FOR REFERRAL PROCESSING & INSURANCE APPROVAL

Include <u>signed</u> and <u>completed</u> order (MD/prescriber to complete page 1)

Include patient demographic information and insurance information

Include patient's medication list

Supporting clinical notes to include any past tried and/or failed therapies, intolerance, benefits, or contraindications to conventional therapy

□ Rheum - Has the patient had a documented contraindication/intolerance or failed trial of a DMARD, NSAID, or conventional therapy (i.e., MTX, leflunomide)? □ Yes □ No If yes, which drug(s)?

□ Rheum - Does the patient have a contraindication/intolerance or failed trial to at least one biologic (i.e., Humira, Simponi, Xeljanz, infliximab)? □ Yes □ No If yes, which drug(s)? _____

CRS dx - Has the patient received treatment with a chimeric antigen receptor T cell therapy (i.e.,

Kymriah, Yescarta) or Blincyto? □ Yes □ No If yes, which drug(s)? ____

Include labs and/or test results to support diagnosis

Rheumatoid Factor or anti-CCP (attach results)

Temporal artery biopsy or cross-sectional imaging or acute-phase reactant elevation (GCA dx)

□ *If applicable* - Last known biological therapy: ______ and last date received: ______. If patient is switching to biologic therapies, please perform a wash-out period of ______ weeks prior to starting Actemra.

Other medical necessity:

REQUIRED PRE-SCREENING

- □ TB screening test completed within 12 months attach results
 □ Positive □ Negative
- Hepatitis B screening test completed (Hepatitis B surface antigen) attach results
 Positive
 Negative

CBC w/diff, LFTs, Lipid Panel - attach results

*If TB or Hepatitis B results are positive - please provide documentation of treatment or medical clearance, and a negative CXR (TB+)

Vital Care will complete insurance verification and submit all required documentation for approval to the patient's insurance company for eligibility. Our team will notify you if any additional information is required. We will review financial responsibility with the patient and refer him/her to any available co-pay assistance as needed. Thank you for the referral.

Please fax all information to (866) 790-3580 or call (945) 212-3707 for assistance

VITALCARE.COM/LOCATIONS/VITAL-CARE-OF-SOUTH-DALLAS/

IMPORTANT NOTICE: This fax is intended to be delivered only to the named address and contains material that is confidential, privileged property, or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.